Business Wire

Boehringer Ingelheim and Partners to Accelerate Development of First-In-Class Gene Therapy for Patients with Cystic Fibrosis

Share

Boehringer Ingelheim, IP Group, the UK Cystic Fibrosis Gene Therapy Consortium (GTC, consisting of researchers from Imperial College London and the Universities of Oxford and Edinburgh) and Oxford Biomedica (OXB), announced today that Boehringer Ingelheim has exercised its options on intellectual property and know-how from the partners to progress and further accelerate the development of a potential, new treatment option for patients with CF. In the partnership, IP Group, acting on behalf of the three GTC host Universities, is granting exclusive global rights to develop, manufacture, register, and commercialize this lentiviral vector-based gene therapy for the treatment of cystic fibrosis. The GTC is additionally contributing its knowledge in pre-clinical research and clinical gene therapy development. OXB is adding its leading competence in manufacturing lentiviral vector-based therapies to Boehringer Ingelheim’s expertise in the development of novel breakthrough therapies for respiratory diseases.

CF is a rare, progressive, life-threatening disease that results in severe dysfunction and persistent infections of the lung affecting 70,000 people worldwide. It is caused by a defective or absent protein that results from mutations in the CFTR gene. This innovative development partnership among academia, life science investors, pharma, and biotech focusses on the advancement of BI 3720931, a novel, replication deficient lentiviral vector, in an inhaled formulation, which selectively introduces a healthy CFTR gene into the relevant target cells.

Professor Eric Alton, Coordinator of the GTC, said: “The novel lung-targeting technology we have developed has demonstrated high gene transfer efficiency in pre-clinical models and offers the possibility of repeated administration to maintain a therapeutic effect, a benefit that other viral-based gene therapies may not be able to provide. Our novel therapy has the potential to improve CFTR function and modify disease in all CF patients, independent of the more than 2,000 different known gene mutations. The immediate target is those patients who are not eligible for CFTR modulators. The GTC is very excited to have reached this milestone after 21 years of focused effort. We are very grateful to our wonderful team and those with CF who have supported us in many ways including taking part in the multiple trials. We would like to thank our funders, both past and present, including the Health Innovation Challenge Fund (a partnership between Wellcome and the Department of Health and Social Care) and Just Gene Therapy, as well as the CF Trust, National Institute for Health Research and the Medical Research Council.”

“Since 2018, Boehringer Ingelheim has sponsored research and development activities with the GTC and OXB. The shared success achieved with our partners in this potentially revolutionary project makes us confident that we can now further accelerate this highly innovative therapeutic approach,” said Clive R. Wood, Ph.D., Corporate Senior Vice President and Global Head of Discovery Research at Boehringer Ingelheim. “With our leadership in the discovery and development of therapies in respiratory diseases combined with the gene therapy and manufacturing knowledge of our partners, we aim to bring the next breakthrough to patients suffering from CF, who are desperately waiting for better options.”

John Dawson, Chief Executive Officer of Oxford Biomedica, said: “We have enjoyed working with Boehringer Ingelheim, IP Group, and the GTC since 2018. Building on the great progress made to date, we are delighted that Boehringer Ingelheim, one of the world’s leading respiratory medicine organizations, has chosen to exercise the option to license OXB lentiviral vector manufacturing technology for this highly innovative inhaled cystic fibrosis gene therapy formulation developed by the GTC. This partnership is central to our company’s mission of delivering life changing gene therapies to patients and has the potential to provide a new therapeutic option for many cystic fibrosis patients globally.”

Under the terms of the option and license agreement with Boehringer Ingelheim, originally announced in August 2018, Boehringer Ingelheim will pay IP Group, on behalf of the GTC, an option exercise fee, near term, success based development, regulatory and sales milestone payments as well as royalties on net sales. OXB will receive an option exercise fee of £3.5 million and will be entitled to payments in an aggregate amount of up to £27.5 million upon achievement of various development, regulatory and sales milestones, in addition to a tiered low single digit royalty on net sales of a cystic fibrosis gene therapy product.

David Ramsden, Chief Executive of the Cystic Fibrosis Trust said: “It is great news that Boehringer Ingelheim have committed to the next stage of the development of a gene therapy treatment for people with cystic fibrosis. This is an important step as it brings hope to the whole cystic fibrosis community and in particular to those who don’t benefit from the currently available medicines. All of those who have helped us to invest long term in the work of the UK CF Gene Therapy Consortium should be proud of what they have made possible.”

Please click on the following link for ‘Notes to Editors’:

http://www.boehringer-ingelheim.com/press-release/cystic-fibrosis-genetherapy-development-option-excercise

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:

Boehringer Ingelheim
Dr Reinhard Malin

Head of Innovation Unit Communications
Boehringer Ingelheim Corporate Center GmbH
Media + PR
P: +49 6132 77-90815
press@boehringer-ingelheim.com

Linda Ruckel
Associate Director, Media and Corporate Reputation
Boehringer Ingelheim U.S.
Media + PR
P: +1 203-791-6672
press@boehringer-ingelheim.com

UK Cystic Fibrosis Gene Therapy Consortium

Imperial College London

Professor Eric Alton
P: +44-207-594-7937
e.alton@ic.ac.uk

Professor Uta Griesenbach
P: +44-207-594-7927
u.griesenbach@ic.ac.uk

Professor Jane Davies
P: +44-207-594-7973
j.c.davies@ic.ac.uk

University of Oxford

Professor Deborah Gill
P: +44-1865 750300
deborah.gill@ndcls.ox.ac.uk

Professor Stephen Hyde
P: +44-1865 750300
steve.hyde@ndcls.ox.ac.uk

University of Edinburgh

Dr Christopher Boyd
P: +44-131-651-8733
chris.boyd@ed.ac.uk

Dr Gerry McLachlan
P: +44-131-651-9162
gerry.mclachlan@roslin.ed.ac.uk

Oxford Biomedica

Mary-Jane Elliott / Matthew Neal
Consilium Strategic Communications: T: +44 (0)20 3709 5700

University of Edinburgh | Oilthigh Dhùn Èideann

Shane Canning
Press Office | Oifis nam Meadhanan
PR & Media Manager (Medicine & Vet Medicine) | Manaidsear PR & na Meadhanan
M 0755 782 0266 | Eshane.canning@ed.ac.uk | @EdinUniMedia

University of Oxford News Office

P: + 44 (0)1865 280528
news.office@admin.ox.ac.uk

Imperial College

Ryan O’Hare
Senior Media Officer
Phone: +44 (0)20 7594 2410
Email: r.ohare@imperial.ac.uk

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Samsung Introduces Three New Logic Solutions to Power the Next Generation of Automobiles30.11.2021 11:00:00 CET | Press release

Samsung Electronics Co., Ltd., a world leader in advanced semiconductor technology, today introduced three of its latest automotive chip solutions; the Exynos Auto T5123 for 5G connectivity, the Exynos Auto V7 for comprehensive in-vehicle infotainment systems, and the ASIL-B certified S2VPS01 power management IC (PMIC) for the Auto V series. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211130005513/en/ Exynos Auto T5123, a 3GPP Release 15 telematics control unit for 5G connectivity solution for automobiles, Exynos Auto V7, a powerful processor for IVI systems in mid to high-end vehicles and S2VPS01, power management IC with ASIL-B certification for the Exynos Auto V series (Graphic: Business Wire) “Smarter and more connected automotive technologies for enriched in-vehicle experiences including entertainment, safety and comfort are becoming critical features on the road,” said Jaehong Park, Executive Vice President of Syste

Soveren Lands Star-Studded $6.5M Seed Round, Including 11 Unicorn Founders, to Fight Privacy Incidents30.11.2021 09:00:00 CET | Press release

Today Soveren announced a $6.5M seed round, led by firstminute capital and joined by Northzone, 11 unicorn founders,and a group of global CEOs. The founders of Airbnb, Datadog, MuleSoft, Snyk, and Color invested alongside Sir Richard Branson’s family, the Chairman CEO of Palo Alto Networks, and others. “Soveren is addressing one of the key technology challenges of the decade: privacy and compliance for Engineering teams. Their product provides CTOs, CISOs, and Privacy Engineers with easy-to-use tools to detect and address privacy gaps. The calibre of their seed round speaks to the pedigree of founders, and to the size of the task ahead,” said Spencer Crawley, Co-Founding General Partner of firstminute capital. Holly Branson, Virgin’s Chief Purpose and Vision Officer said: “At Virgin, our customers mean everything to us and treating them with respect and with world class service is at the core of the entire Virgin ethos. The way we handle their personal information is an important exten

Partech Announces the Closing of Its Second Growth Fund, Partech Growth II, at $750M.30.11.2021 09:00:00 CET | Press release

Partech, the global technology investment firm has announced the closing of Partech Growth II, at €650M (c.$750M) in commitments, significantly above Partech Growth I, raised in 2015 at €400M. The fund, closed above its target size, has seen staunch support from 45+ institutional investors, endowments & foundations, pension funds, life insurers, asset managers and fund-of-funds, and 40+ prominent family offices, entrepreneurs, and business angels, from 10 countries in Europe, North America, and Asia, despite being a mostly remote fundraise due to the pandemic. The fresh capital has already been put to work in five companies in the Czech Republic, France, the Netherlands and Sweden. They include Rohlik - the Prague-based online grocer with full end-to-end operations including procurement, fulfilment, and last mile delivery; Paris-based Skello – the online scheduling and personnel management SaaS tool; Paris-based Rouje – the ultimate French digital native brand of women’s fashion; the A

VicTrack wins Aussie Broadband wholesale deal with ADVA FSP 300030.11.2021 09:00:00 CET | Press release

ADVA (FSE: ADV) today announced that VicTrack is leveraging its state-wide optical transport infrastructure built on ADVA FSP 3000 technology to provide Aussie Broadband with carrier-grade wholesale services. The flexible and fully redundant ROADM network enables VicTrack to easily share capacity. With ADVA’s open optical transport system, it provides VicTrack’s customers with unregenerated optical services between the furthest parts of the state, giving Aussie Broadband access to highly reliable connectivity throughout regional and metro Victoria. Designed for high-capacity and easy scalability, VicTrack’s infrastructure offers unique opportunities for communication service providers (CSPs) to reach new customers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211130005076/en/ ADVA’s open optical technology is helping VicTrack to easily roll out wholesale services. (Photo: Business Wire) “Enabling Aussie Broadband to connec

DE-CIX Expands to the Nordics in Cooperation With Bulk Data Centers30.11.2021 08:05:00 CET | Press release

DE-CIX, the world’s leading Internet Exchange (IX) operator and home to the largest carrier and data center neutral interconnection ecosystem globally, today announces its expansion to the Nordic region. DE-CIX has partnered with Bulk Data Centers, which will house DE-CIX IX platforms in Oslo, Norway (OS-IX), Kristiansand, Norway (Campus N01), as well as in Esbjerg, Denmark (Campus DK01). DE-CIX will also be opening IX platforms in Finland. DE-CIX’s expansion into the Nordic region will open the Nordics to international customers, providing 100 percent green-powered Internet Exchanges through Bulk’s data centers. In addition, local Nordic customers will now get faster and more efficient access to global internet exchange services. “The Nordic region comprises some of the world’s most highly developed digital markets,” says Ivo Ivanov, CEO of DE-CIX International, on the company’s expansion to Northern Europe. “However, the interconnection infrastructure available in the region does not

DE-CIX Expands to the Nordics: New Internet Exchanges for Norway, Denmark, and Finland30.11.2021 08:02:00 CET | Press release

DE-CIX, the world’s leading Internet Exchange (IX) operator and home to the largest carrier and data center neutral interconnection ecosystem globally, today announces its expansion to the Nordic region. DE-CIX will be opening IX platforms in Norway, Denmark, and Finland. “The Nordic region comprises some of the world’s most highly developed digital markets,” says Ivo Ivanov, CEO of DE-CIX International, on the company’s expansion to Northern Europe. “However, the interconnection infrastructure available in the region does not match the digital maturity of the economy in the Nordics. The region has seen significant growth in data center investments for the concentration of hosting, storage and cloud deployments, and a high concentration of enterprises and manufacturing presence. It is important for the related interconnection infrastructure to get closer to these investments, to serve the connectivity demands. DE-CIX has seen strong support from the Nordic data center community for our

Kyoto Semiconductor Announces KP-M Monitor Photodiode "KPDE008LS-A-RA-HQ"30.11.2021 08:00:00 CET | Press release

Kyoto Semiconductor Co., Ltd. (President and CEO Tsuneo Takahashi, Head office: Fushimi-ku, Kyoto city), a leading optical device solution manufacturer with world-class technologies and Japanese quality, has announced the new KP-M monitor photodiode, KPDE008LS-A-RA-HQ. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211129005809/en/ Kyoto Semiconductor KP-M Monitor Photodiode KPDE008LS-A-RA-HQ (Photo: Business Wire) KP-M monitor photodiodes are used to monitor the laser output of optical communication equipment. Higher quality devices are required as the expansion of digital transformation and 5G communications progresses. The "KPDE008LS-A-RA-HQ" has achieved higher quality by adding the probing process at higher temperature. A new wafer prober*1 has been introduced to inspect the electrical characteristics of semiconductor wafers while heated to high temperatures. This allows the inspection to test the temperature (T=75℃) cl